Charles Pilette

Dr. Charles Pilette

Department of Respiratory Medicine, Cliniques Universitaires St-Luc and institute of Experimental and Clinical Research, Université Catholique de Louvain (UCL), 10 Avenue Hippocrate B-1200 Brussels, Belgium

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2015 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
AFAntoine Froidure
Antoine Froidure
JMJonathan Mouthuy
Jonathan Mouthuy
SDStephen R. Durham
Stephen R. Durham
PCPascal Chanez
Pascal Chanez
YSYves Sibille
Yves Sibille
Charles PiletteCharles Pilette
Charles Pilette
The discovery of IgE represented a major breakthrough in allergy and asthma research, whereas the clinical interest given to IgE in asthma has been blurred until the arrival of anti-IgE biotherapy. Novel facets of the complex link between IgE and asthma have been highlighted by the effect of this treatment and by basic research. In parallel, asthma phenotyping recently evolved to the concept of endotypes, relying on identified/suspected pathobiological mechanisms to phenotype patients, but has not yet clearly positioned IgE among biomarkers of asthma.In this review, we first summarise recent knowledge about the regulation of IgE production and its main receptor, FcεRI. In addition to allergens acting as classical IgE inducers, viral infections as well as air pollution may trigger the IgE pathway, notably resetting the threshold of IgE sensitivity by regulating FcεRI expression. We then analyse the place of IgE in different asthma endo/phenotypes and discuss the potential interest of IgE among biomarkers in asthma.

24 June 2021 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
FCFrançois M. Carlier
François M. Carlier
CFCharlotte de Fays
Charlotte de Fays
Charles PiletteCharles Pilette
Charles Pilette
Mucosal surfaces are lined by epithelial cells, which provide a complex and adaptive module that ensures first-line defense against external toxics, irritants, antigens, and pathogens. The underlying mechanisms of host protection encompass multiple physical, chemical, and immune pathways. In the lung, inhaled agents continually challenge the airway epithelial barrier, which is altered in chronic diseases such as chronic obstructive pulmonary disease, asthma, cystic fibrosis, or pulmonary fibrosis. In this review, we describe the epithelial barrier abnormalities that are observed in such disorders and summarize current knowledge on the mechanisms driving impaired barrier function, which could represent targets of future therapeutic approaches.

5 March 2015 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
SGSophie T. Gohy
Sophie T. Gohy
CHCloé Hupin
Cloé Hupin
CFChantal Fregimilicka
Chantal Fregimilicka
BDBruno R. Detry
Bruno R. Detry
CBCaroline Bouzin
Caroline Bouzin
Charles PiletteCharles Pilette
Charles Pilette
In chronic obstructive pulmonary disease (COPD), epithelial changes and subepithelial fibrosis are salient features in conducting airways. Epithelial-to-mesenchymal transition (EMT) has been recently suggested in COPD, but the mechanisms and relationship to peribronchial fibrosis remain unclear. We hypothesised that de-differentiation of the COPD respiratory epithelium through EMT could participate in airway fibrosis and thereby, in airway obstruction.Surgical lung tissue and primary broncho-epithelial cultures (in air–liquid interface (ALI)) from 104 patients were assessed for EMT markers. Cell cultures were also assayed for mesenchymal features and for the role of transforming growth factor (TGF)-β1.The bronchial epithelium from COPD patients showed increased vimentin and decreased ZO-1 and E-cadherin expression. Increased vimentin expression correlated with basement membrane thickening and airflow limitation. ALI broncho-epithelial cells from COPD patients also displayed EMT phenotype in up to 2 weeks of culture, were more spindle shaped and released more fibronectin. Targeting TGF-β1 during ALI differentiation prevented vimentin induction and fibronectin release.In COPD, the airway epithelium displays features of de-differentiation towards mesenchymal cells, which correlate with peribronchial fibrosis and airflow limitation, and which are partly due to a TGF-β1-driven epithelial reprogramming.

12 September 2014 in Allergy
Verified
Journal Article
Closed access
PDF file
CHC. Hupin
C. Hupin
SGS. Gohy
S. Gohy
CBC. Bouzin
C. Bouzin
MLM. Lecocq
M. Lecocq
MPMyriam Polette
Myriam Polette
Charles PiletteCharles Pilette
Charles Pilette

18 January 2013 in Allergy
Verified
Journal Article
Closed access
PDF file
Charles PiletteCharles Pilette
Charles Pilette
MJM. R. Jacobson
M. R. Jacobson
CRC. Ratajczak
C. Ratajczak
BDB. Detry
B. Detry
GBG. Banfield
G. Banfield
KNK. T. Nouri‐Aria
K. T. Nouri‐Aria

3 June 2014 in Allergy
Verified
Journal Article
Closed access
PDF file
AFA. Froidure
A. Froidure
CSC. Shen
C. Shen
DGD. Gras
D. Gras
JSJ. Van Snick
J. Van Snick
PCP. Chanez
P. Chanez
Charles PiletteCharles Pilette
Charles Pilette